ZENYF - ZENYF STOCK NEWS

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has announced the granting of 1,300,000 stock options to its directors, officers, and employees. These options are exercisable at $4.25 per share for a period of three to five years, with a vesting schedule of one-third immediately, one-third after six months, and the final third after twelve months. The company focuses on next-gen healthcare solutions and is commercializing ZENGuard™, a patent-pending antimicrobial coating with 99% efficacy against pathogens, including COVID-19.

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has signed a binding letter of intent with GMAF Circular Medico ApS to produce ZENGuard™-enhanced recyclable surgical masks, branded as Circular PPE™, aimed at reducing environmental impact while enhancing infection control. With a Medical Device Establishment License, Zentek can collaborate globally to sell Class I PPE in Canada. The partnership will explore regulatory requirements in other markets. GMAF's recycling efforts will help minimize waste and carbon emissions in the healthcare sector.

Zentek Ltd. (TSX-V: ZEN and OTC: ZENYF) has commenced receiving direct retail orders for its ZENGuard-enhanced surgical masks following the issuance of its Medical Device Establishment License (MDEL) by Health Canada. The MDEL enables Zentek to produce and sell Class I personal protective equipment (PPE) in Canada, alongside supplying Trebor Rx Corp. with ZENGuard quantities. The CEO highlighted growing public interest in enhanced PPE due to increased awareness of infection control, presenting a potential growth opportunity for the company's innovative products.

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) announced a new R&D test contract from Innovation Solutions Canada to test ZENGuard-coated HVAC filters. The testing aims to validate:

• a reduction in airborne viral load,
• no modifications needed for existing HVAC systems,
• unchanged air flow rates,
• no negative impact on air quality.

Conducted at CREM Co Labs, this initiative highlights the growing need for improved indoor air quality solutions.

Zentek Ltd. (TSX-V:ZEN and OTC:ZENYF) has received a Medical Device Establishment License (MDEL) from Health Canada for manufacturing and distributing class one medical devices. This license facilitates partnerships with manufacturers for the production of ZENGuard antimicrobial-coated surgical masks and other personal protective equipment (PPE) in Canada. The MDEL enables immediate collaboration with PPE manufacturers and extends existing distribution rights even after certain interim orders expire. Zentek aims to address infection control challenges in healthcare settings.

Zentek Ltd. (TSX-V:ZEN, OTC:ZENYF) has filed a preliminary prospectus to distribute 5,129,944 common shares at $5.85 each, totaling gross proceeds of $30,010,172. Underwriters Eight Capital, Leede Jones Gable Inc., and Research Capital Corporation will purchase 3,419,000 shares for $20,001,150, while 1,710,944 shares will be sold directly to purchasers for $10,009,022.40. An over-allotment option allows the purchase of an additional 512,850 shares. Proceeds will fund capital expenses and R&D. Closing is anticipated on December 8, 2021, pending regulatory approval.

Zentek Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) announced key updates on November 11, 2021, including securing a steady supply of graphene oxide for producing ZENGuard™ to coat 3 billion masks. Shipments will commence in December 2021. The company completed warrant acceleration, raising $3.8M from the exercise of 2.5M warrants, leaving no outstanding warrants. Notable management changes include hiring Nick Hansford to bolster strategic planning. The company aims for a Nasdaq listing to enhance liquidity and visibility.

Zentek Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) has made significant advancements in its rapid detection platform for pathogens. The company has partnered with NeoVentures Biotechnology Inc. to validate and optimize its technology, and with axiVEND to enhance biosensor production. Key improvements include a simpler user experience and reduced production time for aptamer-based sensors. Zentek is also formalizing a collaboration with McMaster University for ongoing aptamer development and is actively engaging partners across the supply chain. The CEO emphasizes the unique market advantages of accuracy, speed, and scalability.

Zentek Ltd. (TSX-V:ZEN)(OTC PINK:ZENYF) has been selected as one of three technologies for phase 1 of the Innovation Solutions Canada (ISC) challenge, aiming to develop a portable detection device for SARS-CoV-2 in wastewater. The company received a $148,000 award to create its first prototype. This initiative showcases Zentek's patent-pending DNA aptamer technology, expanding its applications beyond saliva detection. The ISC challenge aims to improve outbreak surveillance and enhance public health data collection.